Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Scopolamine and Sensory Augmentation for Motion Sickness
NCT05886660Phase 2Recruiting
- Sponsor
- Defender Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Placebo
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of placebo gel (Naval Aeromedical Research Unit, Dayton) in motion sickness (4 arms), sponsored by Defender Pharmaceuticals. Primary endpoint: Motion sickness (MS) symptom severity using Pensacola Diagnostic Index (PDI) scale at 45 minutes. Started Jan 2022; status: recruiting.
02
Drugs
placebo gel (Naval Aeromedical Research Unit, Dayton)
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT05886660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886660.